RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SymBio Pharmaceuticals Stock

SymBio Pharmaceuticals Net Income 2024

SymBio Pharmaceuticals Net Income

2.05 B JPY

Ticker

4582.T

ISIN

JP3383050006

WKN

A1JMJE

In 2024, SymBio Pharmaceuticals's profit amounted to 2.05 B JPY, a -204.45% increase from the -1.96 B JPY profit recorded in the previous year.

The SymBio Pharmaceuticals Net Income history

YEARNET INCOME (undefined JPY)
2026e2.88
2025e2.42
2024e2.05
2023-1.96
20221.18
20212.03
2020-4.09
2019-4.38
2018-2.75
2017-3.98
2016-2.31
2015-2.63
2014-1.12
2013-1.61
2012-1.73
2011-2.1
2010-0.64
2009-0.22
20080.02
2007-1.33
2006-0.71

SymBio Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into SymBio Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by SymBio Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects SymBio Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of SymBio Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into SymBio Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing SymBio Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on SymBio Pharmaceuticals’s growth potential.

SymBio Pharmaceuticals Revenue, EBIT and net profit per share

DateSymBio Pharmaceuticals RevenueSymBio Pharmaceuticals EBITSymBio Pharmaceuticals Net Income
2026e14.14 B undefined0 undefined2.88 B undefined
2025e13.81 B undefined0 undefined2.42 B undefined
2024e12.93 B undefined0 undefined2.05 B undefined
20235.59 B undefined-811.67 M undefined-1.96 B undefined
202210.01 B undefined1.96 B undefined1.18 B undefined
20218.26 B undefined1.02 B undefined2.03 B undefined
20202.99 B undefined-4.51 B undefined-4.09 B undefined
20192.84 B undefined-4.3 B undefined-4.38 B undefined
20183.84 B undefined-2.66 B undefined-2.75 B undefined
20173.44 B undefined-3.95 B undefined-3.98 B undefined
20162.37 B undefined-2.13 B undefined-2.31 B undefined
20151.93 B undefined-2.55 B undefined-2.63 B undefined
20141.96 B undefined-1.3 B undefined-1.12 B undefined
20131.53 B undefined-1.68 B undefined-1.61 B undefined
20121.96 B undefined-1.7 B undefined-1.73 B undefined
20111.88 B undefined-2.07 B undefined-2.1 B undefined
20101.45 B undefined-612.8 M undefined-642.3 M undefined
20091.19 B undefined-208 M undefined-217.9 M undefined
20081.63 B undefined132.9 M undefined21 M undefined
20070 undefined-1.33 B undefined-1.33 B undefined
20060 undefined-708 M undefined-711.2 M undefined

SymBio Pharmaceuticals stock margins

The SymBio Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SymBio Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SymBio Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the SymBio Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the SymBio Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the SymBio Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the SymBio Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the SymBio Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the SymBio Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the SymBio Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

SymBio Pharmaceuticals Margin History

SymBio Pharmaceuticals Gross marginSymBio Pharmaceuticals Profit marginSymBio Pharmaceuticals EBIT marginSymBio Pharmaceuticals Profit margin
2026e78.91 %0 %20.37 %
2025e78.91 %0 %17.51 %
2024e78.91 %0 %15.86 %
202378.91 %-14.52 %-35.11 %
202275.94 %19.62 %11.78 %
202170.25 %12.3 %24.61 %
202029.02 %-150.86 %-136.93 %
201930.47 %-151.59 %-154.22 %
201830.58 %-69.25 %-71.76 %
201729.94 %-114.6 %-115.49 %
201638.18 %-89.82 %-97.68 %
201530.16 %-131.99 %-136.15 %
201426.94 %-66.66 %-57.08 %
201320.76 %-109.69 %-104.77 %
201230.33 %-86.96 %-88.65 %
2011-52.1 %-109.8 %-111.79 %
201083.57 %-42.26 %-44.3 %
2009100 %-17.46 %-18.29 %
2008100 %8.15 %1.29 %
200778.91 %0 %0 %
200678.91 %0 %0 %

SymBio Pharmaceuticals Aktienanalyse

What does SymBio Pharmaceuticals do?

SymBio Pharmaceuticals Ltd is a company specializing in the development and marketing of medical products. The company, based in Japan, was founded in 2005 and currently employs over 300 employees. SymBio Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding SymBio Pharmaceuticals's Profit Margins

The profit margins of SymBio Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of SymBio Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating SymBio Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

SymBio Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When SymBio Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about SymBio Pharmaceuticals stock

How much profit has SymBio Pharmaceuticals made this year?

SymBio Pharmaceuticals has made 2.05 B JPY this year.

How has the profit developed compared to last year?

The profit has increased by -204.45% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does SymBio Pharmaceuticals publish its earnings?

SymBio Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of SymBio Pharmaceuticals?

The profits of SymBio Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of SymBio Pharmaceuticals?

You can learn more about the earnings of SymBio Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does SymBio Pharmaceuticals pay?

Over the past 12 months, SymBio Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SymBio Pharmaceuticals is expected to pay a dividend of 0 JPY.

What is the dividend yield of SymBio Pharmaceuticals?

The current dividend yield of SymBio Pharmaceuticals is .

When does SymBio Pharmaceuticals pay dividends?

SymBio Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SymBio Pharmaceuticals?

SymBio Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of SymBio Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is SymBio Pharmaceuticals located?

SymBio Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von SymBio Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SymBio Pharmaceuticals from 8/31/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 8/31/2024.

When did SymBio Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/31/2024.

What was the dividend of SymBio Pharmaceuticals in the year 2023?

In the year 2023, SymBio Pharmaceuticals distributed 0 JPY as dividends.

In which currency does SymBio Pharmaceuticals pay out the dividend?

The dividends of SymBio Pharmaceuticals are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SymBio Pharmaceuticals

Our stock analysis for SymBio Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SymBio Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.